Report not found.
Report not found.
AI-Powered Forecasts for Biotech Investors
ScanScor
The AI Biotech Breakout Prediction Strategy
ScanScor
The AI Biotech Breakout Prediction Strategy
This original EQ prediction has been superseded after later review. The January 20, 2026 thesis relied on an outdated Itolizumab/EQUATOR catalyst as though it were still ahead, but subsequent forensic review showed that key Itolizumab Phase 3 milestones had already occurred in 2025 and were no longer valid as a future breakout driver. In that sense, the original thesis was broken, not because Equillium lacks future potential, but because the prediction was anchored to the wrong catalyst. The company’s forward story later shifted toward EQ504, which belongs under a different thesis and time window.
This prediction was later re-evaluated through a carefully structured NDAPR review, and that process exposed an important pre-StateLock error in the original thesis. The NDAPR prompt was designed to compare breaking news against the exact existing prediction, current company context, and the full recent news trail, forcing the model to decide whether the original catalyst was still valid or had already been resolved. In EQ’s case, that review revealed that the original January 20, 2026 thesis had relied on an outdated Itolizumab/EQUATOR catalyst as though it were still ahead, when in fact the key Phase 3 milestone had already played out in 2025. That discovery did not mean the company had no future potential; it meant the prediction was anchored to the wrong driver. This report also pre-dated StateLock, which was introduced for all predictions starting on 2026-02-27 and has since been applied to the last 33 predictions. StateLock was created specifically to ground each prediction in an authoritative present-state view of the company so that past events are less likely to be mistaken for future catalysts. Had StateLock been in place when this EQ report was written, the thesis likely would have been framed very differently.
For EQ, I would separate three different things:
What I would do with a case like EQ:
Do not delete it. Do not call it wrong. But flag it as “target exceeded pre-window.”
Because what happened may be:
That is not the same as a miss.
I think you need a new category for this type of case, something like:
My preference:
Pre-window target hit
Why this matters:
A stock that exceeds target before the window opens is telling you something important:
That is actually a valuable kind of “error,” because it is not failure — it is a sign that the market moved sooner than expected.
For EQ specifically, I would ask:
If the run is still tied to the same catalyst, then I would keep the thesis ACTIVE and mark the prediction as:
Then at review time, you can decide whether:
So the operational rule I’d suggest is:
If price exceeds target before window start:
That gives you a much more honest reading.
For EQ, my current judgment from what you showed is:
The thesis still appears active, but the original target has been overtaken by price action.
So this is not a broken prediction. It is a prediction that may have been too conservative on upside and too late on its formal window.